|
Synonyms: ACD79B-VCMMAE | polatuzumab vedotin-piiq | Polivy® | RG-7596 | RG7596 | RO5541077-000
polatuzumab vedotin is an approved drug (FDA (2019), EMA (2020))
Compound class:
Antibody
Comment: Polatuzumab vedotin is an antibody drug conjugate containing an anti-CD79b monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches identify US8088378 as the claiming patent [1]. |
| Bioactivity Comments |
| Patent US8088378 identifies clone huMA79b.v28, as the lead, but does not provide an affinity value for this monoclonal's binding to CD79b. The primary target is tagged based on biological evidence provided in the patent. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
